MGFA is dedicated to driving research to better understand, treat and cure myasthenia gravis for good. To achieve this goal, we are committed to creating awareness about clinical trials for those with myasthenia gravis and related neuromuscular joint disorders.
If you would your clinical trial posted to our website, please complete the Research Announcement Form and email to mgfa@myasthenia.org with “Clinical Trial Announcement” in the subject line.
Active Clinical Trials
-
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis. Active and recruiting
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis. Active and recruiting
-
RVT-1401-2002: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RVT- 1401 in Myasthenia Gravis Patients, Active and recruiting
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness, Active and recruiting
-
Catalyst Pharmaceuticals Clinical Trial for Firdapse in MuSK-MG Patients, Active and recruiting
- Exercise for Stable MG, Recruiting
- Innovative measures of speech and swallowing dysfunction in Neurological Disorders (QUESST), Recruiting
-
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis, Active and recruiting
National Health Institute Clinical Trial Research Database
https://clinicaltrials.gov/ct2/results?term=myasthenia&recr=Open